Allogene downgraded by JMP Securities
$ALLO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
JMP Securities downgraded Allogene from Mkt Outperform to Mkt Perform
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/10/2025 | Neutral → Underweight | Analyst | |
| 5/14/2025 | Mkt Outperform → Mkt Perform | Citizens JMP | |
| 3/14/2025 | $5.00 | Mkt Perform → Mkt Outperform | Citizens JMP |
| 8/8/2024 | $13.00 → $11.00 | Outperform | Oppenheimer |
| 5/31/2024 | $11.00 | Overweight | Piper Sandler |
| 1/5/2024 | Mkt Outperform → Mkt Perform | JMP Securities | |
| 1/5/2024 | Buy → Neutral | Guggenheim | |
| 12/8/2023 | $7.00 | Buy | Citigroup |
SCHEDULE 13G/A - Allogene Therapeutics, Inc. (0001737287) (Subject)
10-Q - Allogene Therapeutics, Inc. (0001737287) (Filer)
8-K - Allogene Therapeutics, Inc. (0001737287) (Filer)
4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
4 - Allogene Therapeutics, Inc. (0001737287) (Issuer)
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in three upcoming investor conference in November and December. TD Cowen's Immunology & Inflammation Virtual SummitWednesday, November 121:30PM PT/4:30PM ET Jefferies Global Healthcare Conference in LondonTuesday, November 182:00AM PT/5:00AM ET/10:00AM GMT Piper Sandler 37th Annual Healthcare Conference Tuesday, December 29:00AM PT/12:00PM ET Any available webcasts will be posted to the Company's webs
Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) ALPHA3 Positions Company at the Forefront of MRD-guided, Earlier-Line Oncology TreatmentAdditional Sites in Australia and South Korea Expected to Open in early 2026Scheduled Futility Analysis, Focused on MRD Conversion Between Study Arms, on Track for 1H 2026 Phase 1 RESOLUTION Trial with ALLO-329 in Autoimmune Disease (AID) ALLO-329, a Dual CD19/CD70 CAR, Harnesses the Dagger® Technology to Reduce or Eliminate LymphodepletionRESOLUTION Basket Trial in Rheumatology Enrolling with Proof-of-Concept Data Planned for 1H 2026 Phase 1 TRAVERSE Trial with
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that a Trial-in-Progress (TIP) poster highlighting the pivotal Phase 2 ALPHA3 trial evaluating cemacabtagene ansegedleucel (cema-cel) will be presented at the 2025 American Society of Hematology (ASH) Annual Meeting in Orlando, Florida. ALPHA3 is a randomized study with two arms, comparing cema-cel administered following standard FC lymphodepletion versus observation, the current standard of care. The poster will highlight the i
Analyst downgraded Allogene from Neutral to Underweight
Citizens JMP downgraded Allogene from Mkt Outperform to Mkt Perform
Citizens JMP upgraded Allogene from Mkt Perform to Mkt Outperform and set a new price target of $5.00
Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) ALPHA3 Positions Company at the Forefront of MRD-guided, Earlier-Line Oncology TreatmentAdditional Sites in Australia and South Korea Expected to Open in early 2026Scheduled Futility Analysis, Focused on MRD Conversion Between Study Arms, on Track for 1H 2026 Phase 1 RESOLUTION Trial with ALLO-329 in Autoimmune Disease (AID) ALLO-329, a Dual CD19/CD70 CAR, Harnesses the Dagger® Technology to Reduce or Eliminate LymphodepletionRESOLUTION Basket Trial in Rheumatology Enrolling with Proof-of-Concept Data Planned for 1H 2026 Phase 1 TRAVERSE Trial with
Conference Call and Webcast Scheduled for November 6, 2025 at 2:00 p.m. PT/5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report the third quarter 2025 financial results and provide a business update on November 6, 2025, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET. Listen-Only WebcastThe listen-only webcast will be made available on the Company's website a
Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) ALPHA3 Proceeding as a Two-Arm Randomized Trial Comparing Cema-cel After Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion vs. ObservationMore than 50 sites Activated Across the U.S. and Canada, with Additional International Expansion Underway; Scheduled Futility Analysis Remains on Track for 1H 2026 Phase 1 RESOLUTION Trial with ALLO-329 in Autoimmune Disease (AID) Initiated RESOLUTION Basket Trial in RheumatologyProof-of-Concept Data Remains Planned for 1H 2026 Phase 1 TRAVERSE Trial with ALLO-316 in Renal Cell Carcinoma (RCC)
SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Alison Moore, Ph.D., as an independent member of its Board of Directors. Dr. Moore brings over 25 years of executive experience in the biotechnology and pharmaceutical industry, including an extensive background in cell therapy manufacturing. She currently serves as Chief Technical Officer (CTO) of Codexis Inc. (NASDAQ:CDXS), a leading enzyme engineering company, and was the former CTO of Allog
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, has appointed Geoffrey Parker as Executive Vice President, Chief Financial Officer. Mr. Parker will oversee the Company's financial operations and business strategy and will serve as a member of the Leadership Team. "Geoff's extensive experience in biotechnology across all aspects of finance and business development strategy will be of tremendous value to Allogene as we advance our critical pipeline assets and explore new opportunities," said David Chang, M.D., Ph.D.
SOUTH SAN FRANCISCO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that Earl Douglas has been appointed as General Counsel. Mr. Douglas will oversee all aspects of the Company's legal function and serve as a member of the Leadership Team. "We are excited to welcome Earl who brings a tenure of experience guiding publicly-traded biotech companies on complex legal issues, corporate strategy and transactions," said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene. "I also want to th
SC 13G/A - Allogene Therapeutics, Inc. (0001737287) (Subject)
SC 13G - Allogene Therapeutics, Inc. (0001737287) (Subject)
SC 13G/A - Allogene Therapeutics, Inc. (0001737287) (Subject)